Roche to file MS drug for approval in early 2016; Bristol-Myers' Opdivo scores Early Access spot in U.K.; Boehringer diabetes med falls short in Phase II;

> Roche ($RHHBY) touted success for its MS drug ocrelizumab in two late-stage studies, saying the data puts it on track for regulatory filings in early 2016. Report

> Bristol-Myers Squibb's ($BMY) new cancer immuno-therapy Opdivo scored a spot on the U.K.'s Early Access to Medicines Scheme, the first lung cancer drug to be approved under the program. Report

> Boehringer Ingelheim and its development partner Vitae ($VTAE) saw their diabetes drug VTP-34072 fail to significantly decrease blood sugar in a mid-stage trial. Report

> AstraZeneca's ($AZN) Crestor patent was invalidated by the Brazilian federal courts. Report

> Novartis' ($NVS) eye care unit Alcon won European approval for a new type of lens used in cataract surgery. Release

> Cosmederm Bioscience expanded its itch-relief product line TriClam with two new topical products. Release

And Finally... WPP-owned brand agency The Partners appointed Peter Henshaw from Inventiv Europe as a creative director for its health team. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.